- Home
- JDZG vs CGTX Comparison
JDZG vs CGTX Comparison
Compare JDZG & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JDZG
- CGTX
- Stock Information
- Founded
- JDZG 2020
- CGTX 2007
- Country
- JDZG China
- CGTX United States
- Employees
- JDZG N/A
- CGTX N/A
- Industry
- JDZG Other Consumer Services
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- JDZG Real Estate
- CGTX Health Care
- Exchange
- JDZG Nasdaq
- CGTX Nasdaq
- Market Cap
- JDZG 15.2M
- CGTX 17.2M
- IPO Year
- JDZG 2024
- CGTX 2021
- Fundamental
- Price
- JDZG $0.58
- CGTX $0.42
- Analyst Decision
- JDZG
- CGTX Strong Buy
- Analyst Count
- JDZG 0
- CGTX 6
- Target Price
- JDZG N/A
- CGTX $8.30
- AVG Volume (30 Days)
- JDZG 100.1K
- CGTX 2.9M
- Earning Date
- JDZG 11-27-2024
- CGTX 05-06-2025
- Dividend Yield
- JDZG N/A
- CGTX N/A
- EPS Growth
- JDZG N/A
- CGTX N/A
- EPS
- JDZG 0.06
- CGTX N/A
- Revenue
- JDZG $2,334,771.00
- CGTX N/A
- Revenue This Year
- JDZG N/A
- CGTX N/A
- Revenue Next Year
- JDZG N/A
- CGTX N/A
- P/E Ratio
- JDZG $9.45
- CGTX N/A
- Revenue Growth
- JDZG 52.08
- CGTX N/A
- 52 Week Low
- JDZG $0.45
- CGTX $0.34
- 52 Week High
- JDZG $15.08
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- JDZG N/A
- CGTX 28.70
- Support Level
- JDZG N/A
- CGTX $0.39
- Resistance Level
- JDZG N/A
- CGTX $0.45
- Average True Range (ATR)
- JDZG 0.00
- CGTX 0.05
- MACD
- JDZG 0.00
- CGTX -0.00
- Stochastic Oscillator
- JDZG 0.00
- CGTX 21.57
About JDZG JIADE LIMITED Common stock
Jiade Ltd Ltd is engaged in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platforms and auxiliary solutions. The Group offers pre-enrollment guidance on school/selection and application development, training for entrance exams, and assistance in the application process. The Group also offers offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance in the People's Republic of China.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.